# EKSO BIONICS HOLDINGS, INC. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/EKSO BIONICS HOLDINGS, INC.). ## Overview Ekso Bionics Holdings, Inc. designs and markets wearable robotic exoskeletons that help people regain mobility in rehabilitation settings and support workers in industrial environments. The company’s core business centers on the EksoNR and Ekso Indego product families, plus related services such as training, maintenance, and extended warranty support. ## Products & services • EksoNR rehabilitation exoskeleton • Ekso Indego Therapy clinical exoskeleton • Ekso Indego Personal mobility device • EVO industrial ergonomic exoskeleton • EksoCare extended warranty and premium support • Device servicing, repair, and training - **Enterprise Health exoskeletons** (70%) — Clinical robotic exoskeletons used in rehabilitation settings for gait training and mobility support. - **Personal Health exoskeletons** (15%) — Devices sold to individual users for personal mobility and home use, supported by reimbursement efforts. - **Industrial exoskeletons** (5%) — EVO products sold to commercial and industrial customers to reduce ergonomic strain and improve productivity. - **Services and support** (10%) — EksoCare, repairs, maintenance, loaner devices, and training tied to installed devices. - EksoNR rehabilitation exoskeleton - Ekso Indego Therapy clinical exoskeleton - Ekso Indego Personal mobility device - EVO industrial ergonomic exoskeleton - EksoCare extended warranty and premium support - Device servicing, repair, and training ## Customers Ekso sells primarily to healthcare providers that use its devices in rehabilitation programs, especially inpatient rehabilitation facilities and larger integrated delivery networks. It also sells to individual users in the Personal Health market and to industrial employers seeking ergonomic solutions for repetitive overhead work. A smaller portion of demand comes from distributors and financing partners that support subscription-style transactions. - **Inpatient rehabilitation facilities** (primary) — Buy EksoNR and Ekso Indego Therapy for supervised neurorehabilitation and gait training. - **Integrated delivery networks** (primary) — Purchase multiple units across hospital networks to standardize rehab programs and improve economics. - **Personal Health users** (secondary) — Buy Ekso Indego Personal for individual mobility support, often dependent on reimbursement coverage. - **Industrial and commercial employers** (secondary) — Buy EVO to address ergonomic challenges, especially overhead and repetitive work tasks. - **Distributors and finance partners** (secondary) — Enable indirect sales, subscription financing, and broader geographic reach. - Inpatient rehabilitation facilities buy EksoNR and Ekso Indego Therapy for gait rehab - Integrated delivery networks buy multi-unit clinical deployments - Personal Health users buy Ekso Indego Personal for mobility support - Industrial employers buy EVO to reduce injury and fatigue risk - Finance partners support subscription sales to end customers - Clinicians buy training and support to deploy devices safely ## Geography Ekso operates across the Americas, EMEA, and APAC, with direct sales strongest in the Americas and a mix of direct and distributor channels elsewhere. The company specifically notes direct coverage in German-speaking countries within EMEA, while other EMEA and APAC markets are served through distributors or mixed channels. Recent revenue pressure came from weaker Enterprise Health device sales in EMEA, while the Americas saw growth in both Enterprise and Personal Health device sales. - Americas sales are primarily direct and are a key growth region - EMEA uses a mix of direct and distributor channels - German-speaking EMEA countries are handled directly - APAC is served through direct and indirect channels by country - EMEA weakness hurt recent revenue, while Americas offset part of it ## Strategy Ekso is focused on expanding reimbursement and clinical adoption for its Personal Health products while continuing to sell into rehabilitation centers and network providers. It is also broadening its enterprise offering with complementary products such as BalanceTutor and pursuing strategic transactions, which suggests management is actively evaluating portfolio and corporate structure options. - **Expand reimbursement for Personal Health** (short-term) — Coverage by more insurers would widen the addressable market and reduce reliance on limited CMS reimbursement. - **Deepen enterprise clinical adoption** (medium-term) — Winning larger rehab networks can improve pipeline visibility and lower selling costs through multi-unit deployments. - **Expand product portfolio with complementary offerings** (medium-term) — New products can increase wallet share and create cross-selling opportunities in existing customer accounts. - **Evaluate strategic alternatives** (short-term) — A strategic transaction could reshape the company’s capital structure, ownership, or business mix. - Expand insurance coverage beyond CMS for Personal Health devices - Broaden indications of use to support reimbursement and adoption - Target larger rehab networks and strategic clinical centers - Add complementary products like BalanceTutor to the enterprise portfolio - Commercialize Nomad after clinical feedback and study results - Explore strategic transactions, including possible sale of the business ## Risks Ekso depends on adoption in a specialized healthcare market, reimbursement progress, and continued access to capital, all of which can be volatile for a small medical-device company. The business also faces execution risk from manufacturing costs, cybersecurity exposure, and the uncertainty around strategic transactions that could materially change the company’s future. - **Reimbursement and coverage risk** [high] — Personal Health demand depends on insurance coverage beyond CMS and broader indications of use. - **Clinical adoption and market acceptance** [high] — Hospitals and rehab networks must see clear clinical and economic value before buying multi-unit systems. - **Manufacturing cost and supply execution** [high] — The company has not yet significantly reduced manufacturing cost, which can limit gross margin improvement. - **Cybersecurity and data protection** [medium] — Devices and portals process sensitive patient and proprietary data, creating breach and disruption risk. - **Strategic transaction uncertainty** [high] — The company is exploring transactions that could involve a sale of the business or major dilution. - Reimbursement risk limits Personal Health adoption and slows commercialization - Clinical adoption depends on proving economic and therapeutic value - Manufacturing costs may not fall as planned, pressuring margins - Cybersecurity and data handling risks affect operations and customer trust - Strategic transaction uncertainty could distract management and dilute holders - Foreign exchange and regional demand swings can affect reported results ## Accounting Ekso’s reported results are sensitive to revenue recognition judgments, especially for device sales, subscriptions, and bundled service arrangements. Investors should also watch fair value estimates for warrant liabilities, inventory valuation, warranty reserves, and deferred tax asset recoverability, since these can move earnings and balance sheet values materially. - **Revenue recognition and standalone selling prices** — Can shift revenue between periods and affect gross margin comparability - **Warrant liabilities fair value** — Can create volatile non-cash earnings swings - **Inventory valuation** — Directly affects gross profit and inventory write-down risk - **Warranty and service reserves** — Affects operating expense and liability estimates - **Deferred tax asset recoverability** — Can materially affect balance sheet valuation allowances - Revenue allocation across device and service obligations affects timing of revenue - Subscription arrangements require judgment on contract terms and control transfer - Warrant liability fair value can create large non-cash gains or losses - Inventory valuation affects gross margin when demand or obsolescence changes - Warranty and credit loss estimates can change with installed base performance - Lease and long-lived asset lives affect expense timing and carrying values --- *Last updated: 2026-04-28T20:02:53.965064+00:00*